 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results PR Newswire SOUTH...

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results

PTC Therapeutics, Inc. (NASDAQ:PTCT  Get Free Report) has been given a consensus recommendation of Reduce by the thirteen analysts that are presently covering the company...

PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Recommendation of "Reduce" by Brokerages

PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA PR Newswire SOUTH PLAINFIELD, N.J., March 28, 2024...

PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA

PTC Therapeutics (NASDAQ:PTCT  Get Free Report) had its target price raised by equities research analysts at Jefferies Financial Group from $33.00 to $35.00 in a report issued on Wednesday...

PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $35.00 at Jefferies Financial Group

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

ClearPoint congratulates partner PTC Therapeutics on completion of its BLA

PTC Therapeutics Provides Key Regulatory Updates PTC Therapeutics Provides Key Regulatory Updates PR Newswire SOUTH PLAINFIELD, N.J., March 19, 2024 -BLA submitted to FDA for Upstaza for the...

PTC Therapeutics Provides Key Regulatory Updates

This is a Bearish indicator signaling PTCT's price could decline from here. Traders may explore shorting the stock or put options...

PTC Therapeutics (PTCT, $29.58) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 15, 2024

This is a signal that PTCT's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

PTC Therapeutics (PTCT, $28.91) Stochastic Oscillator left the overbought zone on March 14, 2024

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT  Get Free Report) have been assigned an average rating of Reduce from the fifteen brokerages that are currently covering the...

Brokerages Set PTC Therapeutics, Inc. (NASDAQ:PTCT) Price Target at $34.40

PTC Therapeutics (NASDAQ:PTCT  Free Report) had its target price hoisted by Royal Bank of Canada from $22.00 to $28.00 in a research report sent to investors on Friday morning, Benzinga...

PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $28.00

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Volume (M)	3.93M
52-Wk High	$59.84
52-Wk Low	$17.53

PTCT PTC Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals